Chronic myelogenous leukemia future or investigational therapies: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(One intermediate revision by one other user not shown)
Line 2: Line 2:
{{Chronic myelogenous leukemia}}
{{Chronic myelogenous leukemia}}
Please help WikiDoc by adding content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.
Please help WikiDoc by adding content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.
While imatinib drastically changed the management of CML, advanced-generation TKIs have the potential to transform the current approach to treatment. Resistance and intolerance to imatinib require alternative therapies. High-dose imatinib does not consistently demonstrate a benefit in newly diagnosed patients; however, in patients with previous cytogenetic response and lack of mutations, this strategy can overcome resistance due to subtherapeutic levels of the drug. A substantial amount of data confirm the safety and efficacy of dasatinib and nilotinib after imatinib failure. In newly diagnosed patients with CML, dasatinib and nilotinib demonstrate similar rates of response, and shorten the time to achievement of clinical milestones. Data for front-line therapy with these agents require additional follow-up before conclusive outcomes on survival can be assessed. Currently available TKIs provide no benefit for patients who harbor the T315I mutation; however, investigational therapies such as omacetaxine and AP24534 display encouraging results in this subset of patients.21299461


==References==
==References==
Line 13: Line 15:
{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Hematology]]
[[Category:Immunology]]

Latest revision as of 20:24, 10 May 2018

Chronic myelogenous leukemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Chronic myelogenous leukemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Chronic myelogenous leukemia future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Chronic myelogenous leukemia future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Chronic myelogenous leukemia future or investigational therapies

CDC on Chronic myelogenous leukemia future or investigational therapies

Chronic myelogenous leukemia future or investigational therapies in the news

Blogs on Chronic myelogenous leukemia future or investigational therapies

Directions to Hospitals Treating Chronic myelogenous leukemia

Risk calculators and risk factors for Chronic myelogenous leukemia future or investigational therapies

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

While imatinib drastically changed the management of CML, advanced-generation TKIs have the potential to transform the current approach to treatment. Resistance and intolerance to imatinib require alternative therapies. High-dose imatinib does not consistently demonstrate a benefit in newly diagnosed patients; however, in patients with previous cytogenetic response and lack of mutations, this strategy can overcome resistance due to subtherapeutic levels of the drug. A substantial amount of data confirm the safety and efficacy of dasatinib and nilotinib after imatinib failure. In newly diagnosed patients with CML, dasatinib and nilotinib demonstrate similar rates of response, and shorten the time to achievement of clinical milestones. Data for front-line therapy with these agents require additional follow-up before conclusive outcomes on survival can be assessed. Currently available TKIs provide no benefit for patients who harbor the T315I mutation; however, investigational therapies such as omacetaxine and AP24534 display encouraging results in this subset of patients.21299461

References


Template:WikiDoc Sources